[Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]

[Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]

INTRODUCTION: Disease Modifying Therapies (DMTs) have significantly improved clinical conditions of Relapsing Remitting Multiple Sclerosis (RRMS) patients. However, several unmet needs are still relevant in RRMS. Recently, a new therapy, delayed-release dimethyl-fumarate (DMF; also known as gastro-r...

Full description

Bibliographic Details
Main Authors: Gianluca Furneri, Laura Santoni, Chiara Marchesi, Sergio Iannazzo, Paolo Angelo Cortesi, Achille Patrizio Caputi, Lorenzo Giovanni Mantovani
Format: Article
Language:English
Published: SEEd Medical Publishers 2016-06-01
Series:Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:
disease modifying therapies
multiple sclerosis
cost-effectiveness
Online Access:https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1251

Similar Items

Similar Items